Certain adults with this artery-blocking condition may see more benefits with an open bypass compared to less-invasive procedures to improve circulation.
November 15, 2022
Bypass Surgery Favorable for Initial Treatment of Chronic Limb-Threatening Ischemia
November 15, 2022 Performing open bypass surgery to restore circulation for people with a severe form of peripheral…
Read More
Edwin A. Takahashi, M.D., assistant professor of radiology in the division of interventional radiology at the Mayo Clinic College of Medicine in Rochester, Minnesota. Copyright Mayo Clinic College of Medicine
November 15, 2022
Telehealth is a Valuable Option in Cardiovascular Care, Though Challenges Remain
November 15, 2022 — Telehealth is a proven and valuable option for people with cardiovascular disease, however, there…
Read More
UMSOM researchers display first genetically modified pig heart transplanted into living patient. Image courtesy of University of Maryland School of Medicine
November 15, 2022
Unexpected Electrical Changes Seen in First Successful Transplant of Genetically-Modified Pig Heart
November 15, 2022 — Ten months after transplanting the first genetically-modified pig heart into a human patient,…
Read More
When it comes to heart failure (HF), sex differences are known to impact everything from risk factors to clinical presentation to response to treatment, making sex a key factor to consider in studies of emerging pharmacotherapies.
November 14, 2022
Study Shows Heart Failure Treatment With Dapagliflozin Consistently Benefited Both Men and Women
November 14, 2022 — When it comes to heart failure (HF), sex differencesare known to impact everything from risk…
Read More
Less complex heart patients may benefit, but not without risk
November 14, 2022
Largest Randomized Trial Evaluates Steroids for Infant Heart Surgery
November 14, 2022 — For more than four decades, doctors have been split on whether giving steroids during a pediatric…
Read More
Reduction in the risk of death or major bleeding after primary PCI in patients with STEMI treated with heparin monotherapy (blue curve) or bivalirudin with a post-procedure infusion (red curve). The hazard ratio of 0.69 signifies a 31% reduction in risk. The ARR (absolute risk reduction) was 1.3%. The NNT (number of patients needed to treat to prevent one death or large bleed) was 76. Image courtesy of Mount Sinai Health System
November 14, 2022
Bivalirudin Found to be Safer and More Effective Than Heparin for Treating Heart Attack Patients Undergoing Percutaneous Coronary Intervention
November 14, 2022 — Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the…
Read More
The "Trending Topics at Sessions 2022" panel of experts featured Manesh R. Patel, MD, FACC, FAHA, Chair of the Committee on AHA 2022 Scientific Sessions, to review highlights and lessons learned from the event.
November 14, 2022
AHA 2022 Trending Topics: Clinical Trials, Scientific Studies and AI
November 14, 2022 — The American Hospital Association Scientific Sessions 2022, held Nov. 5-7 in Chicago, IL, presented…
Read More
Investigators Compared AFib Patients Treated with Catheter Ablation to Those Treated with Anti-arrhythmic Drugs Only
November 10, 2022
Study Finds Catheter Ablation Significantly Lowers Risk of Dementia in Patients with Atrial Fibrillation
November 10, 2022 —  Biosense Webster, Inc., the global leader in cardiac arrhythmia treatment and part of Johnson…
Read More
Cryoablation involves guiding a small tube into the heart and inflating a small balloon to kill problematic tissue with cold temperatures. Image courtesy of Medtronic
November 10, 2022
National Study Suggests It's Time to Rethink How We Treat Atrial Fibrillation
November 10, 2022 —  A national study led by UBC researchers at the Centre for Cardiovascular Innovation is shedding…
Read More
When the SARS-CoV-2 protein Nsp6 is made in a fruit fly heart (center), the heart has structural defects compared to a normal heart without the viral protein (left). When fruit fly hearts with the viral Nsp6 protein are given the metabolism changing drug 2DG (right), the hearts begin to look more normal than the ones with the viral protein that do not have the drug. Image courtesy of Zhe Han at UMSOM
November 10, 2022
How a SARS-CoV-2 Virus Protein Damages the Heart
November 10, 2022 —  Researchers at the University of Maryland School of Medicine’s (UMSOM) Center for Precision…
Read More
Findings from the BEST-CLI trial presented at the American Heart Association Scientific Sessions (AHA2022) indicate optimal treatment for patients with limb-threatening ischemia.  
November 10, 2022
BEST-CLI Clinical Trial Focuses on Optimal Treatment for Limb-Threatening Ischemia
November 10, 2022 ­– Significant findings from the clinical trial, known as “BEST-CLI — Best Endovascular versus Best…
Read More
80-year-old patient with nonischemic dilated cardiomyopathy. Ejection fraction was 25.2%. Patient underwent cardiac MRI. A. Radial strain overlay on short-axis cine image and corresponding graph show global radial strain measurement, yielding value of 10.8%. B. Circumferential strain overlay on short-axis cine image and graph show global circumscribed strain measurement, yielding value of -8.5%. C. Longitudinal strain overlay on 4-chamber cine image and graph show global longitudinal strain measurement, yie
November 09, 2022
Myocardial Strain Parameters on MRI in Patients With Dilated Cardiomyopathy
November 9, 2022 — According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR), left…
Read More
Risk Reductions of 46% to 52% for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30- and 90-Days Following Hospital Discharge
November 09, 2022
New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure
November 9, 2022 —  Lexicon Pharmaceuticals, Inc. announced that a new analysis of results from the SOLOIST-WHF Phase 3…
Read More
Risk Reductions of 46% to 52% for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30- and 90-Days Following Hospital Discharge
November 09, 2022
CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific Sessions
November 9, 2022 — CinCor Pharma, Inc. announced the presentation today of Phase 2 data from its BrigHtn trial as part…
Read More
By Bhvita Jani
November 09, 2022
Interventional X-ray and Mobile C-arm Equipment Markets Had a Double-digit Recovery in 2021
The world market for interventional X-ray and mobile C-arm equipment is forecast to reach over $4.9 billion by 2026,…
Read More
November 09, 2022
American Heart Association Honors Distinguished Scientists at AHA22
November 9, 2022 — Seven awardees were honored during the American Heart Association Scientific Sessions (AHA 2022).…
Read More
Tech tools are creating positive change in Cardiac MRI Software Market
By Christine Book
November 09, 2022
AI-powered Software Solutions Enhance Cardiac Diagnostics
Interventional cardiologists know well the phrase “change is the only constant.” This is especially relevant as…
Read More
Artificial intelligence-powered alternative data is driving novel and disruptive market research opportunities at a staggering clip amid category growth forecasts, prompting industries of every size and sort to capitalize on this strategy that’s ever evolving and innovating 
By Merilee Kern, MBA
November 09, 2022
AI-Powered Alternative Data Driving Extreme Market Research Disruption
Numerous indicators make clear that the next five years will usher in extreme transformation for a multitude of…
Read More
New genomic therapies for cardiovascular disease are reaching the clinical trial stage, according to moderators of a session presented at the American Heart Association Annual Scientific Session (AHA2022).
November 08, 2022
Progress Reported on Clinical Trials of Genomic Profiling for Cardiovascular Disease at AHA 2022
November 8, 2022 — Genomic-based therapies for cardiovascular disease are emerging fast in research, and could soon be…
Read More
Robert J. Mentz, M.D., Associate Professor of Medicine, Chief, Heart Failure Section, Associate Program Director, Duke Cardiology Fellowship, Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, image copyright Robert J. Mentz
November 08, 2022
TRANSFORM-HF Trial Found No Difference in Effectiveness Between 2 Common Loop Diuretics
November 8, 2022 — After hospital discharge for heart failure, people treated with either loop diuretic medication…
Read More
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now